Page last updated: 2024-11-06

glycyl-histidyl-lysine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycyl-histidyl-lysine: found in human plasma; promotes proliferation of hepatoma cells, lymphocytes & mycoplsma; maintains viability of hepatocytes, eosinophils and macrophages; inhibits growth of glial cells; RN given refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Gly-His-Lys : A tripeptide composed of glycine, L-histidine and L-lysine residues joined in sequence. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
GlycinegenusA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID73587
CHEMBL ID1814493
CHEBI ID75430
SCHEMBL ID259085
SCHEMBL ID19087235
MeSH IDM0075195

Synonyms (48)

Synonym
49557-75-7
iamin
liver cell growth factor
glycyl-l-histidyl-l-lysine
CHEMBL1814493 ,
chebi:75430 ,
gly-l-his-l-lys
bdbm50350478
AKOS016003505
glycylhistidyllysine
copper(ii)ghk
nsc 379527
glycyl-histidyl-lysine
unii-39tg2h631e
copper glycyl-histidyl-lysine
gly-his-lys
39tg2h631e ,
n(2)-(n-glycyl-l-histidyl)-l-lysine
SCHEMBL259085
AC-31946
oristar ghk
tripeptide-1
prezatide
growth-modulating peptide (human)
l-lysine, glycyl-l-histidyl-
pc-1020 free base
c.p.p.
kollaren
ghk [mi]
tripeptide-1 [inci]
gly-his-lys-oh
(s)-6-amino-2-((s)-2-(2-aminoacetamido)-3-(1h-imidazol-4-yl)propanamido)hexanoic acid
glycyl-l-histidyl-l-lysine (h-gly-l-his-l-lys-oh)
DTXSID30197831
(2s)-6-amino-2-[(2s)-2-(2-aminoacetamido)-3-(1h-imidazol-5-yl)propanamido]hexanoic acid
c14h24n6o4
DB11296
SCHEMBL19087235
DS-14630
EX-A7713
CS-0005654
D92811
A871782
I10329
BG162807
HY-P0046
AKOS040758595
ghk-cu(2:1)

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" It was shown by employing various biophysical studies that P6 interact with Aβ and prevent the formation of toxic Aβ forms like oligomeric species and fibrillar aggregates."( Natural Tripeptide-Based Inhibitor of Multifaceted Amyloid β Toxicity.
Govindaraju, T; Madhu, C; Rajasekhar, K, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
chelatorA ligand with two or more separate binding sites that can bind to a single metallic central atom, forming a chelate.
vulneraryA drug used in treating and healing of wounds.
hepatoprotective agentAny compound that is able to prevent damage to the liver.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
tripeptideAny oligopeptide that consists of three amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 2Homo sapiens (human)Ki3,095.15000.79434.22108.0000AID612540
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
monoatomic ion transportSolute carrier family 15 member 2Homo sapiens (human)
protein transportSolute carrier family 15 member 2Homo sapiens (human)
peptide transportSolute carrier family 15 member 2Homo sapiens (human)
peptidoglycan transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic transportSolute carrier family 15 member 2Homo sapiens (human)
dipeptide transportSolute carrier family 15 member 2Homo sapiens (human)
renal absorptionSolute carrier family 15 member 2Homo sapiens (human)
regulation of nucleotide-binding domain, leucine rich repeat containing receptor signaling pathwaySolute carrier family 15 member 2Homo sapiens (human)
dipeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
tripeptide import across plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
antibacterial innate immune responseSolute carrier family 15 member 2Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 15 member 2Homo sapiens (human)
proton transmembrane transportSolute carrier family 15 member 2Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Processvia Protein(s)Taxonomy
protein bindingSolute carrier family 15 member 2Homo sapiens (human)
peptide:proton symporter activitySolute carrier family 15 member 2Homo sapiens (human)
tripeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
dipeptide transmembrane transporter activitySolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
phagocytic vesicle membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
membraneSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
extracellular exosomeSolute carrier family 15 member 2Homo sapiens (human)
apical plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
plasma membraneSolute carrier family 15 member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID612540Binding affinity to human PepT2 in SKTP cells2011Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15
Fragmental modeling of hPepT2 and analysis of its binding features by docking studies and pharmacophore mapping.
AID1191421Bacteriostatic activity against Pseudomonas aeruginosa PCM 2562 (ATCC9027) after 16 to 20 hrs by broth micro-dilution method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections.
AID1191419Antimicrobial activity against Staphylococcus aureus after 16 to 20 hrs by broth micro-dilution method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections.
AID1191420Bacteriostatic activity against Staphylococcus aureus after 16 to 20 hrs by broth micro-dilution method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections.
AID1191418Antimicrobial activity against Escherichia coli after 16 to 20 hrs by broth micro-dilution method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (88)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (23.86)18.7374
1990's20 (22.73)18.2507
2000's11 (12.50)29.6817
2010's25 (28.41)24.3611
2020's11 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.13 (24.57)
Research Supply Index4.62 (2.92)
Research Growth Index4.91 (4.65)
Search Engine Demand Index41.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.04%)5.53%
Reviews8 (8.16%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other88 (89.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]